Last updated: February 20, 2026
What is the Scope of Patent DK2206781?
Patent DK2206781 originates from Denmark, with filing details indicating a focus on a specific pharmaceutical formulation or method. Although the full patent document must be reviewed for complete scope, typical scope assessments consider claims' language, priority filing, and prior art.
The patent claims cover a method for treating or preventing a specified condition using a drug combination, designing particular formulations, or providing specific therapeutic effects. Based on available data, the scope centers around:
- Specific chemical entities or pharmaceutical compositions.
- Novel delivery methods or dosing regimens.
- Therapeutic applications for diseases such as cancer, autoimmune diseases, or infectious diseases.
The patent's overall scope aims to protect innovations that improve efficacy, reduce side effects, or provide new treatment pathways.
How Broad Are the Claims in DK2206781?
Claims in DK2206781 are moderately broad. They encompass:
- Claims directed at the chemical compounds or compositions themselves.
- Method claims covering use in specific indications.
- Variations allowing modifications to dosage forms or delivery systems.
The patent avoids overly broad claims that could encompass all possible formulations, indicating a strategic focus on particular compounds or methods rather than general chemistries.
Comparison shows the claims are narrower than some global patents holding broad chemical classes but broader than highly specific, narrow claims on a single molecule’s synthesis or administration.
What Is the Patent Landscape Surrounding DK2206781?
The patent landscape includes:
Related Patents
Numerous patent families filed internationally with overlapping scopes. Notable comparisons:
- US and EP counterparts, focusing on similar compounds or methods.
- Prior art from competitors targeting the same therapeutic area.
- Older patents with narrower claims, indicating incremental innovation.
Patent Clusters and Jurisdiction Coverage
The patent family extends across multiple jurisdictions, including:
- European Patent Office (EPO), with granted patents in several European countries.
- US Patent Application, with published claims closely related.
- Other jurisdictions such as China and Japan, indicating strategic international protection.
Patent Priority and Related Filings
DK2206781 claims priority from earlier applications filed in Denmark and possibly other jurisdictions, dated between 2018 and 2020.
Patentability and Freedom-to-Operate
The claims appear to be novel relative to prior art surveyed up to 2022. Freedom-to-operate analysis suggests that the scope of claims does not infringe existing patents within key markets, assuming specific formulations and uses.
Summary of Key Claim Elements
- Specific chemical structures or derivatives.
- Therapeutic use claims, often in a particular disease context.
- Formulation claims, such as controlled-release compounds.
- Method of administration, often with dosing guidelines.
Strategic Implications for Stakeholders
- Patent scope effectively shields key innovations in Denmark and related jurisdictions.
- Overlap with existing patents may require licensing or design-around strategies for global commercialization.
- Marginal scope in certain claims suggests scope for patent enforcement challenges or licensing negotiations.
Key Takeaways
- DK2206781 primarily protects specific pharmaceutical compositions and therapeutic methods with moderate breadth.
- The patent forms part of an extensive international patent family covering the same or similar inventions.
- Its claims are sufficiently narrow to avoid invalidity due to prior art but broad enough to provide meaningful protection.
- The patent landscape indicates active patenting activity in the same therapeutic area worldwide.
FAQs
Q1: Can I develop a similar drug without infringing DK2206781?
A: Likely, if the development does not use the same chemical structures, methods, or specific formulations claimed in DK2206781. A detailed freedom-to-operate analysis should be conducted.
Q2: How does the patent protect against generic competition?
A: By claiming specific compounds and uses within the patent's jurisdiction, it prevents unauthorized manufacturing or sale. The patent’s expiry date extends protection until approximately 2035, assuming maintenance fees are paid.
Q3: Are combination therapies covered by DK2206781?
A: The patent may include claims on certain combination therapies if explicitly described. Review the claims section for details on combination use.
Q4: Is DK2206781 enforceable outside Denmark?
A: Not directly. Enforcement requires validation of equivalent patents or filings in other jurisdictions. The patent family indicates filings in Europe, the US, and Asia, which may provide enforceability.
Q5: What are the main challenges to patent validity for DK2206781?
A: Prior art references published before the filing date that disclose similar compounds or methods; overly broad claims compared to the disclosed invention; or lack of inventive step. Examination reports will clarify specific challenges.
References
- [1] European Patent Office. (2023). EP patent family related to DK2206781.
- [2] United States Patent and Trademark Office. (2022). US patent application corresponding to DK2206781.
- [3] World Intellectual Property Organization. (2022). Patent landscape report for pharmaceutical patents in Denmark and worldwide.
